Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04963764 · ClinicalTrials.gov registry record · Early Phase 1
Procalcitonin to Reduce Antibiotic Use in Pediatric Pneumonia
A Early Phase 1 study of Pneumonia and Community-acquired Pneumonia, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 5
- Enrollment target
- 3
- Study locations
NCT04963764: Completed Early Phase 1 study of Pneumonia and Community-acquired Pneumonia, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
NCT04963764 is a Early Phase 1 study of Pneumonia and Community-acquired Pneumonia that has completed, run by Ann & Robert H Lurie Children's Hospital of Chicago. The registered enrollment target is 5 participants, below the 4,519-participant average among 47 other Pneumonia trials with a reported enrollment target (100% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04963764, a Early Phase 1 study of Pneumonia and Community-acquired Pneumonia, has completed, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 5 participants
- Enrollment target
- 3
- Study locations
Study Summary
This pilot study will evaluate study processes and feasibility of a future large-scale clinical trial that proposes to test whether low-risk children managed as outpatients with community-acquired pneumonia (CAP) and procalcitonin (PCT) levels \<0.25 ng/mL treated with placebo have a similar clinical response to those treated with antibiotics and fewer adverse effects.
Primary Outcome
Number of patients enrolled in Stage 2 (Randomized Pilot Trial) per site
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Amoxicillin
Study Locations (3)
Illinois
- Ann & Robert H Lurie Children's Hospital of Chicago - Chicago
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Pennsylvania
- The Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2021-10-18 |
| Est. Completion | 2022-05-27 |
| Phase | Early Phase 1 |
What the finished NCT04963764 record still lists
NCT04963764 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 4,519-participant average among 47 other Pneumonia trials with a reported enrollment target (100% lower).
The record links to 4 conditions, with Pneumonia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04963764 reports a single indexed study location in Illinois, Ohio, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04963764 about?
NCT04963764 is a clinical study titled "Procalcitonin to Reduce Antibiotic Use in Pediatric Pneumonia". This pilot study will evaluate study processes and feasibility of a future large-scale clinical trial that proposes to test whether low-risk children managed as outpatients with community-acquired pneumonia (CAP) and procalcitonin (PCT) levels \<0.25 ng/mL treated with placebo have a similar clinica...
What is the current status of trial NCT04963764?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2021-10-18. Estimated completion is 2022-05-27.
What conditions does trial NCT04963764 study?
This clinical trial studies the following conditions: Pneumonia, Community-acquired Pneumonia, Pediatric Respiratory Diseases, Antibiotic Use.
What interventions are being tested in trial NCT04963764?
The interventions under investigation include: Placebo (DRUG), Amoxicillin (DRUG).
Who is sponsoring clinical trial NCT04963764?
This trial is sponsored by Ann & Robert H Lurie Children's Hospital of Chicago, which has 159 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04963764 being conducted?
This trial has 3 study locations across Illinois, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pneumonia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04963764's enrollment target sits among peer trials
5 48th of 47 the lowest of 47 other Pneumonia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pneumonia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
iNO300 Therapy in Critically Ill Patients With Pneumonia
RECRUITING · Early Phase 1
-
The APS Phenotyping Study
RECRUITING
-
Reducing Overuse of Antibiotics With Decision Support
RECRUITING · NA
-
Extending Dental Care to Nursing Home Residents to Reduce Mouth Infections and Incidence of Pneumonia and Improve Diabetic Glucose Control
RECRUITING · NA
-
Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU
RECRUITING · NA
-
A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI